Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
Em Crescimento
A empresa está em fase de crescimento, com a receita anual mais recente totalizando US$ 1.54M.
Alto Crescimento de Lucro
O lucro líquido da empresa lidera o setor, com o lucro anual mais recente totalizando US$ 1.54M.
Avaliação Justa
O PE mais recente da empresa é -8.72, em uma faixa percentil média de 3 anos.
Venda Institucional
As participações institucionais mais recentes são de 75.58M ações, uma redução de 7.88% em relação ao trimestre anterior.